Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence,

Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report -
       Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ:
VNDA), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), Prana Biotechnology
Limited (NASDAQ: PRAN), and Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On November 15, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that
the French National Agency for Medicines and Health Products Safety has
granted an Autorisation Temporaire d'Utilisation de cohorte, or Temporary
Authorization for Use, for patient sales of Vimizim for the treatment of
Morquio A Syndrome. According to BioMarin, the ATU allows patients with
Morquio A Syndrome in France to receive treatment with Vimizim before
marketing authorization for the product is granted in the European Union. Jeff
Ajer, Senior Vice President, Global Commercial Operations at BioMarin, stated,
"We look forward to working closely with European regulatory authorities
through the final stages of full market approval in this region." The Full
Research Report on BioMarin Pharmaceutical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN

--

Vanda Pharmaceuticals, Inc. Research Report

On November 14, 2013, Vanda Pharmaceuticals, Inc. (Vanda) announced that the
US Food and Drug Administration's (FDA) Peripheral and Central Nervous System
Drugs Advisory Committee (Advisory Committee) voted overwhelmingly to
recommend the approval of the New Drug Application (NDA) for tasimelteon, with
proposed trade name HETLIOZ, for the treatment of Non-24-Hour Disorder
(Non-24) in the totally blind. Commenting on the recommendation, Mihael H.
Polymeropoulos M.D., Vanda's President and CEO, said, "We are now one step
closer toward our goal of providing a treatment option that addresses the
physiologic cause of this serious, debilitating orphan condition that impacts
a majority of totally blind individuals." The Full Research Report on Vanda
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b5ad_VNDA

--

Cadence Pharmaceuticals Inc. Research Report

On November 14, 2013, Cadence Pharmaceuticals Inc. (Cadence) announced that
the US District Court for the District of Delaware has ruled in favor of
Cadence in relation to the Company's patent infringement lawsuit against Exela
Pharma Sciences, LLC. Ted Schroeder, President and CEO of Cadence, commented,
"We are very pleased with the Court's decision, as it confirms our belief in
the strength and validity of the patents covering OFIRMEV." Schroeder added,
"Our focus remains on continuing to drive OFIRMEV's strong performance. We
continue to gain market share and posted year-over-year sales growth of more
than 100% in each quarter of 2013. We remain confident in our franchise, and
look forward to updating investors further on our progress." The Full Research
Report on Cadence Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/f5e5_CADX

--

Prana Biotechnology Limited Research Report

On November 15, 2013, Prana Biotechnology Limited (Prana) issued an official
response regarding a news story which indirectly reference Prana's Phase II
clinical drug trial of PBT2 for Alzheimer's disease, IMAGINE. Prana informed
that it was neither aware of the segment and nor did it participate in the
segment, and the Company, the clinical investigators, and the patients
involved are unaware of the treatment assignment (PBT2 or a placebo). The
Company further reported that the IMAGINE trial is a randomised, double-blind
trial, whose results are expected to be released in March 2014. . Prana
reported that it issued this official response under ASX Guidance Note 8
Continuous Disclosure to avoid any uncertainty and has not received a request
from the ASX. The Company expects to release the results of IMAGINE in March
2014. The Full Research Report on Prana Biotechnology Limited - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9f3a_PRAN

--

Biostar Pharmaceuticals, Inc. Research Report

On November 14, 2013, Biostar Pharmaceuticals, Inc. (Biostar) released its Q3
2013 results. Biostar registered net sales of $15.0 million, up 50.1% YoY in
Q3 2013. The Company posted comprehensive income of $1.7 million in Q3 2013,
compared to comprehensive loss of $6.1 million in Q3 2012. Biostar reported
diluted EPS of $0.03 in Q3 2013, compared to diluted loss per share of $0.63
in Q3 2012. Ronghua Wang, Chairman of Biostar, commented, "Thanks to the
efforts of our entire team and the continued support shown in our market
channel by both consumers and our suppliers, for the nine months ended
September 30, 2013, the Company achieved sales revenue of $41.75 million, cash
flow from operations of $13.71 million, and net profits of $0.22 million." The
Full Research Report on Biostar Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9687_BSPM

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.